Key Points
- Ra Capital Management, L.P. director sold 171,963 shares of Vor Biopharma on April 20 at an average price of $15.77, totaling about $2.71 million, leaving them with 2,567,245 shares (a reported 6.28% ownership decrease).
- Ra Capital conducted a string of large sales throughout April, offloading roughly 2.84 million shares for approximately $46.8 million in total, signaling substantial ongoing insider selling.
- Vor Biopharma shares trade near $15 (market cap ~$741M) while Wall Street consensus is a “Moderate Buy” with an average price target of about $50.56, implying significant analyst upside versus current levels.
Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 171,963 shares of the company's stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $15.77, for a total transaction of $2,711,856.51. Following the transaction, the director directly owned 2,567,245 shares of the company's stock, valued at approximately $40,485,453.65. This trade represents a 6.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Friday, April 17th, Ra Capital Management, L.P. sold 458,411 shares of Vor Biopharma stock. The shares were sold at an average price of $16.28, for a total transaction of $7,462,931.08.
- On Monday, April 13th, Ra Capital Management, L.P. sold 530,610 shares of Vor Biopharma stock. The shares were sold at an average price of $16.15, for a total transaction of $8,569,351.50.
- On Wednesday, April 15th, Ra Capital Management, L.P. sold 53,644 shares of Vor Biopharma stock. The shares were sold at an average price of $16.01, for a total transaction of $858,840.44.
- On Tuesday, April 14th, Ra Capital Management, L.P. sold 153,735 shares of Vor Biopharma stock. The shares were sold at an average price of $15.97, for a total transaction of $2,455,147.95.
- On Friday, April 10th, Ra Capital Management, L.P. sold 828 shares of Vor Biopharma stock. The shares were sold at an average price of $15.75, for a total transaction of $13,041.00.
- On Thursday, April 9th, Ra Capital Management, L.P. sold 135,201 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total transaction of $2,242,984.59.
- On Wednesday, April 8th, Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock. The shares were sold at an average price of $16.48, for a total transaction of $7,978,033.92.
- On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total transaction of $9,775,773.63.
- On Thursday, April 2nd, Ra Capital Management, L.P. sold 260,000 shares of Vor Biopharma stock. The shares were sold at an average price of $18.23, for a total transaction of $4,739,800.00.
Vor Biopharma Price Performance
Shares of NASDAQ VOR opened at $15.17 on Wednesday. Vor Biopharma Inc. has a 1 year low of $2.62 and a 1 year high of $65.80. The company's 50-day moving average is $14.80 and its 200 day moving average is $15.82. The stock has a market capitalization of $741.05 million, a P/E ratio of -0.04 and a beta of 1.92.
Institutional Investors Weigh In On Vor Biopharma
A number of hedge funds and other institutional investors have recently bought and sold shares of VOR. RA Capital Management L.P. grew its holdings in Vor Biopharma by 172.7% in the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company's stock worth $70,697,000 after purchasing an additional 3,422,697 shares during the period. Fcpm Iii Services B.V. grew its holdings in Vor Biopharma by 852.8% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company's stock worth $47,315,000 after purchasing an additional 3,237,714 shares during the period. Frazier Life Sciences Management L.P. purchased a new stake in Vor Biopharma in the fourth quarter worth about $33,275,000. Paradigm Biocapital Advisors LP purchased a new stake in Vor Biopharma in the fourth quarter worth about $22,890,000. Finally, NEXTBio Capital Management LP purchased a new stake in Vor Biopharma in the fourth quarter worth about $13,080,000. Hedge funds and other institutional investors own 97.29% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the stock. Wells Fargo & Company assumed coverage on shares of Vor Biopharma in a research report on Thursday, March 19th. They set an "overweight" rating and a $30.00 price target on the stock. Wall Street Zen upgraded shares of Vor Biopharma from a "strong sell" rating to a "hold" rating in a research report on Saturday, April 4th. HC Wainwright reduced their price target on shares of Vor Biopharma from $32.00 to $31.00 and set a "buy" rating on the stock in a research report on Wednesday, April 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Vor Biopharma in a report on Wednesday, January 21st. Finally, Citigroup initiated coverage on shares of Vor Biopharma in a report on Friday, January 9th. They issued a "buy" rating and a $50.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $50.56.
View Our Latest Research Report on Vor Biopharma
About Vor Biopharma
(
Get Free Report)
Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.
The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
